Transaction details and shareholding
Gregory L. Weaver, Altimmune, Inc.'s Chief Financial Officer, bought 5,000 shares of the company's common stock on March 6, 2026, at $3.54 per share. The acquisition totaled $17,700. After that purchase, Weaver's direct holdings in Altimmune amount to 28,078 shares.
Share performance context
The purchase occurred against a backdrop of recent weakness in Altimmune's share price. Over the last week the stock declined by nearly 15% and, at the time of the disclosure, was trading closer to its 52-week low of $2.90 than its 52-week high of $7.73.
Balance-sheet and valuation notes
According to InvestingPro analysis cited in the disclosure, Altimmune's balance sheet shows the company holding more cash than debt. The same analysis, however, indicates the stock appears overvalued when compared with InvestingPro's Fair Value assessment. The filing referenced InvestingPro as a source for expanded research and Pro Research Reports covering a broad set of U.S. equities.
Quarterly results and analyst reaction
Altimmune reported fourth-quarter 2025 results that missed expectations on both the bottom line and top line. Earnings per share were -$0.27, missing the consensus forecast of -$0.25 and representing an EPS surprise of -8%. Revenue for the quarter came in at $26 million versus anticipated revenue of $625 million.
Following the company's Phase IIb IMPACT trial results for pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH), William Blair reiterated a Market Perform rating on Altimmune. William Blair observed that pemvidutide demonstrated therapeutic activity in the trial but did not show clear clinical differentiation within the competitive MASH landscape.
Competitive environment
The clinical and commercial backdrop referenced in the filing includes competitors such as Madrigal's Rezdiffra and Novo Nordisk's Wegovy, along with emerging programs from Boehringer Ingelheim and Eli Lilly. The combination of challenging trial positioning and the reported quarterly shortfalls frames the near-term hurdles the company faces.
Bottom line
The insider purchase by Altimmune's CFO represents a direct personal investment of $17,700 and modestly increases his stake to 28,078 shares. At the same time, the company is contending with material quarterly misses and a competitive therapeutic landscape, while third-party analysis highlights a stronger cash position but a valuation above its assessed fair value.
Key points
- Altimmune CFO Gregory L. Weaver bought 5,000 shares on March 6, 2026, at $3.54 each, spending $17,700; his total direct holdings are 28,078 shares.
- Fourth-quarter 2025 EPS was -$0.27 versus an expected -$0.25 (an -8% surprise), and revenue was $26 million compared with $625 million expected.
- InvestingPro analysis cited that Altimmune holds more cash than debt but appears overvalued against InvestingPro's Fair Value assessment; William Blair kept a Market Perform rating after Phase IIb pemvidutide results showed activity without clear differentiation.
Risks and uncertainties
- Clinical differentiation: Pemvidutide showed therapeutic activity but did not demonstrate clear clinical differentiation in MASH, raising uncertainty about its competitive positioning - relevant to biotech and pharmaceutical investors.
- Financial performance: The company reported a larger-than-expected EPS loss and a significant revenue shortfall, introducing near-term earnings and cash-flow uncertainty - relevant to equity and credit markets.
- Valuation concerns: Third-party assessment indicating the stock may be overvalued relative to fair value creates uncertainty for investors assessing upside potential - relevant across equity valuation and portfolio allocation decisions.